Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Non Operating Income (2018 - 2023)

Acro Biomedical has reported Non Operating Income over the past 6 years, most recently at $789.0 for Q2 2023.

  • Quarterly results put Non Operating Income at $789.0 for Q2 2023, up 273.93% from a year ago — trailing twelve months through Jun 2023 was $2863.0 (up 257.88% YoY), and the annual figure for FY2025 was $52878.0, up 1318.67%.
  • Non Operating Income for Q2 2023 was $789.0 at Acro Biomedical, roughly flat from $788.0 in the prior quarter.
  • Over the last five years, Non Operating Income for ACBM hit a ceiling of $2503.0 in Q1 2021 and a floor of -$826.0 in Q3 2019.
  • Median Non Operating Income over the past 5 years was $355.0 (2022), compared with a mean of $541.67.
  • Biggest five-year swings in Non Operating Income: tumbled 308.33% in 2020 and later skyrocketed 667.57% in 2021.
  • Acro Biomedical's Non Operating Income stood at -$440.0 in 2019, then soared by 589.77% to $2155.0 in 2020, then tumbled by 90.63% to $202.0 in 2021, then skyrocketed by 289.6% to $787.0 in 2022, then rose by 0.25% to $789.0 in 2023.
  • The last three reported values for Non Operating Income were $789.0 (Q2 2023), $788.0 (Q1 2023), and $787.0 (Q4 2022) per Business Quant data.